Dade Behring Marburg Gmbh

Loyola University of Chicago

Martin M&uuml;ller

Lutz Gissmann

Conrad Bleul

The invention relates to seroreactive regions on proteins E1 and E2 of human papillomavirus (HPV) 16. The application also relates to a vaccine which contains such peptides which contain the seroreactive regions. The invention likewise embraces compositions for diagnostic purposes which contain peptides with the seroreactive regions.

Antibodies specific for seroreactive regions on HPV 16 protein E1

The invention relates to seroreactive regions on the E1 and E2 proteins of human papillomavirus 16 (HPV 16). The invention also relates to a vaccine that contains peptides comprising at least one seroreactive region of the E1 and/or E2 proteins. The invention likewise embraces compositions for diagnostic purposes, which contain peptides with the seroreactive regions. Further, the invention relates to antibodies that bind to seroreactive regions of the E1 and/or E2 proteins of HPV 16, and compositions comprising such antibodies, which can be used for diagnostic purposes.

Antibodies that specifically react with seroreactive regions on HPV 16 proteins E1 and E2

Seroreactive epitopes on proteins of human papillomavirus (HPV) 18

Vaccine formulations comprising viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed.

Papilloma virus capsomere formulations and method of use

The invention relates to seroreactive regions on protein E1 and E2 of human papillomavirus (HPV) 16. The application also relates to a vaccine which contains such peptides which contain the seroreactive regions. The invention likewise embraces compositions for diagnostic purposes which contain peptides with the seroreactive regions.

Growing community of inventors

Heidelberg, Germany

Martin Müller

Growing community of inventors

Heidelberg, Germany

Martin M&uuml;ller

Martin Müller